Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study

Geert A. Simkens; Thijs R. van Oudheusden; Hidde J. Braam; Marinus J. Wiezer; Simon W. Nienhuijs; Harm J. Rutten; Bert van Ramshorst; Ignace H. de Hingh

doi:10.1002/jso.24169

Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study

Geert A. Simkens, Thijs R. van Oudheusden, Hidde J. Braam, Marinus J. Wiezer, Simon W. Nienhuijs, Harm J. Rutten, Bert van Ramshorst, Ignace H. de Hingh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Web of Science)

Abstract

The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P?=?0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P?=?0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P?=?0.987).Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. ? 2016? 2016

Original language	English
Pages (from-to)	548-553
Journal	Journal of Surgical Oncology
Volume	113
Issue number	5
DOIs	https://doi.org/10.1002/jso.24169
Publication status	Published - 1 Apr 2016

Keywords

colorectal neoplasms
rectal neoplasms
neoplasms metastases
treatment outcome
peritoneum

Access to Document

10.1002/jso.24169

Cite this

Simkens, G. A., van Oudheusden, T. R., Braam, H. J., Wiezer, M. J., Nienhuijs, S. W., Rutten, H. J., van Ramshorst, B., & de Hingh, I. H. (2016). Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study. Journal of Surgical Oncology, 113(5), 548-553. https://doi.org/10.1002/jso.24169

@article{585803dd854d4a0495d2562dff92d6f5,

title = "Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study",

abstract = "The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P?=?0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P?=?0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P?=?0.987).Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. ? 2016? 2016",

keywords = "colorectal neoplasms, rectal neoplasms, neoplasms metastases, treatment outcome, peritoneum",

author = "Simkens, {Geert A.} and {van Oudheusden}, {Thijs R.} and Braam, {Hidde J.} and Wiezer, {Marinus J.} and Nienhuijs, {Simon W.} and Rutten, {Harm J.} and {van Ramshorst}, Bert and {de Hingh}, {Ignace H.}",

year = "2016",

month = apr,

day = "1",

doi = "10.1002/jso.24169",

language = "English",

volume = "113",

pages = "548--553",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley",

number = "5",

}

Simkens, GA, van Oudheusden, TR, Braam, HJ, Wiezer, MJ, Nienhuijs, SW, Rutten, HJ, van Ramshorst, B & de Hingh, IH 2016, 'Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study', Journal of Surgical Oncology, vol. 113, no. 5, pp. 548-553. https://doi.org/10.1002/jso.24169

Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study. / Simkens, Geert A.; van Oudheusden, Thijs R.; Braam, Hidde J. et al.

In: Journal of Surgical Oncology, Vol. 113, No. 5, 01.04.2016, p. 548-553.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study

AU - Simkens, Geert A.

AU - van Oudheusden, Thijs R.

AU - Braam, Hidde J.

AU - Wiezer, Marinus J.

AU - Nienhuijs, Simon W.

AU - Rutten, Harm J.

AU - van Ramshorst, Bert

AU - de Hingh, Ignace H.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P?=?0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P?=?0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P?=?0.987).Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. ? 2016? 2016

AB - The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P?=?0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P?=?0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P?=?0.987).Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. ? 2016? 2016

KW - colorectal neoplasms

KW - rectal neoplasms

KW - neoplasms metastases

KW - treatment outcome

KW - peritoneum

U2 - 10.1002/jso.24169

DO - 10.1002/jso.24169

M3 - Article

C2 - 27110701

VL - 113

SP - 548

EP - 553

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 5

ER -